Sarah Ross
Merck & Co. (NYSE:MRK), the New Jersey drugmaker behind blockbuster treatments like Keytruda, finds itself in Washington's crosshairs this week. A bipartisan group of lawmakers has opened a national security review into how Merck and fellow pharmaceutical giant AbbVie have conducted clinical trials inside China, and the scrutiny is landing at a moment when Merck shares are already trading near the top of their yearly range.
At a Glance
- Merck trades at 128.5 USD, down 0.68% on the day
- Market capitalization stands at 317.77 billion dollars
- 52 week range runs from 107.9 to 130.29
- P/E ratio of 35.99 with EPS reflecting that multiple
- Dividend yield of 2.65% and RSI reading of 68.01
| Price | 128.5 USD |
|---|---|
| Day change | -0.88 (-0.68%) |
| 52-week range | 107.9 – 130.29 |
| Market cap | $317.77B |
| P/E ratio | 35.99 |
| EPS (ttm) | 3.57 |
| Dividend yield | 2.65% |
| RSI (14) | 68.01 |
| Volume | 11,837,218 |
What Triggered the Congressional Letters
Rep. John Moolenaar, the Michigan Republican who leads the House Select Committee on China, signed letters dated Monday demanding that Merck and AbbVie hand over detailed information by July 17. Lawmakers want to know how each company screens trial sites, safeguards patient data, and enforces safety protocols, with particular attention paid to facilities in Xinjiang and hospitals tied to China's military apparatus.
The committee's own research points to a long history of overseas trial work. Merck has reportedly participated in 224 clinical studies across China since 2005, and at least 31 of those were run in Xinjiang while 40 took place at sites connected to the Chinese military. AbbVie's footprint since 2007 includes more than 100 studies, among them 17 in Xinjiang and 16 at military linked institutions.
The letters, sent to Merck chief executive Robert Davis and AbbVie chief executive Robert Michael, stop well short of accusing either company of breaking any law. But they raise a pointed concern: that running trials inside Chinese military hospitals could expose valuable biotechnology intellectual property to transfer risk. Lawmakers also flagged Xinjiang as the site of what they term genocide against Uyghurs and other minority groups, and cited Chinese research documenting failures to properly obtain informed consent from some trial participants.
Merck has responded by saying patient safety and ethical conduct remain central to its clinical research operations and that it adheres to global regulatory standards wherever it operates. China's embassy in Washington pushed back sharply, with a spokesperson calling the committee's actions lacking in credibility and accusing the United States of politicizing trade and technology matters. AbbVie, for its part, did not directly address the investigation, though the company's newer immunology drugs Skyrizi and Rinvoq have been picking up the slack as its former flagship product Humira loses ground to biosimilar competitors.
The Bigger Biotech Rivalry
This isn't happening in isolation. American officials have grown increasingly uneasy about China's expanding footprint in drug development. One figure cited alongside the investigation shows China's share of global early stage drug development jumped from 8% in 2015 to more than 32% by 2024, while the American share fell from 48% down to roughly 37% across that same stretch. The Biosecure Act, which President Trump signed into law last year, already restricts federal agencies from doing business with certain non-U.S. biotech firms, a sign that this kind of scrutiny is becoming a fixture of policy rather than a one-off event.
What the Numbers Say
Merck's stock closed at 128.5 USD, slipping 0.68% for the session but still sitting close to its 52 week high of 130.29, well above the low of 107.9 set earlier in the cycle. That positioning near the top of the range, combined with an RSI of 68.01, suggests the stock is approaching overbought territory, a technical signal that momentum traders watch closely even though it doesn't guarantee a pullback.
Valuation tells a more complicated story. A P/E ratio of 35.99 is rich for a pharmaceutical company of Merck's size and maturity, implying investors are pricing in continued earnings growth or confidence that recent product strength, particularly from Keytruda, will persist. The 317.77 billion dollar market cap places Merck firmly among the largest healthcare companies globally, and the 2.65% dividend yield offers income seeking investors a reason to stay put even amid headline risk.
The bull case rests on Merck's diversified pipeline and its dividend track record, both of which have kept long term shareholders loyal through past controversies. The bear case centers on regulatory overhang: a congressional investigation, even one that stops short of alleging wrongdoing, can weigh on sentiment if it drags into broader restrictions on China based research or triggers reputational damage. Combined with a stretched valuation and an RSI flirting with overbought levels, the stock may be more vulnerable to negative headlines than its steady dividend and market position might suggest.
Frequently Asked Questions
What exactly are lawmakers investigating at Merck?
The House Select Committee on China is examining Merck's clinical trial practices in China, particularly at sites in Xinjiang and hospitals linked to the Chinese military, asking the company to detail its vetting and data protection procedures by July 17.
Has Merck been accused of breaking any laws?
No. The congressional letters explicitly state that neither Merck nor AbbVie is known to have violated any laws, though lawmakers cite national security and ethical concerns tied to the trial locations.
How has Merck's stock performed relative to its yearly range?
Merck shares closed at 128.5 USD, near the top of their 52 week range of 107.9 to 130.29, despite a slight daily decline of 0.68%.
What is the Biosecure Act and how does it relate to this story?
The Biosecure Act, signed into law by President Trump last year, restricts federal agencies from conducting business with certain non-U.S. biotechnology companies, reflecting a broader government push to limit reliance on Chinese biotech infrastructure.
Where This Leaves Merck Investors
The investigation adds a layer of political risk to a stock already trading at elevated valuations and technical levels that suggest strong recent buying pressure. Whether the inquiry escalates into tangible business restrictions or fades as a procedural matter will likely shape sentiment more than the underlying fundamentals in the near term.
Connor Simmons
Chris Wood